Press releases
- Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
- Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
- Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
- Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
- GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern Europe
- Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
- Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
- Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Thursday, Deciphera Pharmaceuticals Inc (D05:FRA) closed at 14.41, -9.63% below its 52-week high of 15.94, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.98 |
---|---|
High | 14.41 |
Low | 13.98 |
Bid | -- |
Offer | -- |
Previous close | 13.69 |
Average volume | 2.50 |
---|---|
Shares outstanding | 80.80m |
Free float | 56.16m |
P/E (TTM) | -- |
Market cap | 1.27bn USD |
EPS (TTM) | -2.29 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 15:51 BST.
More ▼